AXNX - Axonics Modulation expects strong Q4 growth
For Q4, Axonics Modulation Technologies (AXNX) expects net revenue to be in the range of $34.7-$34.9M vs. $9.9M reported in the year ago quarter.U.S. customers sales represented ~97% of total revenue.In Q4, ~320 confirmed and scheduled permanent implants were canceled due to COVID-19 based upon a detailed territory by territory analysis; cancellations accounted for ~$5M of revenue that was neither shipped nor invoiced in Q4.FY20 revenue is estimated at ~$111.5M vs. $13.8M in FY19."We remain bullish on the growth outlook for Axonics and the SNM market in 2021 and beyond," CEO Raymond W. Cohen commented.Earnings scheduled for Mar.3 release.
For further details see:
Axonics Modulation expects strong Q4 growth